Taltz® ▼ (ixekizumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Taltz Summary of Product Characteristics (SmPC)

Taltz® ▼ (ixekizumab): Method of Administration in Adults

Ixekizumab is for subcutaneous injection.

Administration Instructions

Ixekizumab is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Ixekizumab is indicated.1

Ixekizumab is for subcutaneous injection. Injection sites may be alternated. If possible, areas of the skin that show psoriasis should be avoided as injection sites. The solution/the syringe must not be shaken.1

Each ixekizumab injection is to be administered

  • at a different anatomic location (such as upper arms, thighs, or any quadrant of the abdomen) than the previous injection, and

  • not into areas where the skin is tender, bruised, erythematous, indurated, or affected by psoriasis.2

Administration into the upper outer arm may be performed by a caregiver or healthcare provider.2

After proper training in subcutaneous injection technique, patients may self-inject ixekizumab if a healthcare professional determines that it is appropriate. However, the physician should ensure appropriate follow-up of patients. Comprehensive instructions for administration are given in the package leaflet and the user manual.1

Device Options

There are 2 presentations for ixekizumab.

  • Ixekizumab 80 mg/ml solution is contained in a single-dose prefilled pen.

  • Ixekizumab 80 mg/ml solution is contained in a single-dose prefilled syringe.1

References

1. Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: June 17, 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question